A method for determining whether hypotension caused by novel compounds in preclinical development results from histamine release

Author： Blom J.D.   Yang P.-C.   Nicholson N.S.   Case B.L.   Parlow J.J.   South M.S.   Wegner C.D.  

Publisher： Elsevier

ISSN： 1056-8719

Source： Journal of Pharmacological and Toxicological Methods, Vol.49, Iss.1, 2004-01, pp. : 31-37

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Histamine modulation of glutamate release from hippocampal synaptosomes

By Rodriguez F.J.   Lluch M.   Dot J.   Blanco I.   Rodriguez-Alvarez J.  

European Journal of Pharmacology, Vol. 323, Iss. 2, 1997-04 ,pp. : 283-286

Elsevier

Access to resources Recommend Favorite

Preclinical investigations into the antipsychotic potential of the novel histamine H 3 receptor antagonist GSK207040

By Southam Eric  

Psychopharmacology, Vol. 201, Iss. 4, 2009-01 ,pp. : 483-494

Springer Publishing Company

Access to resources Recommend Favorite

The Preclinical Testing Strategy for the Development of Novel Chemical Entities for the Treatment of Asthma

By  

Current Drug Targets, Vol. 9, Iss. 6, 2008-06 ,pp. : 443-451

Bentham Science Publishers

Access to resources Recommend Favorite

The Pharmacokinetic Principles Behind Scaling from Preclinical Results to Phase I Protocols

By Mahmood I.   Balian J.D.  

Clinical Pharmacokinetics, Vol. 36, Iss. 1, 1999-01 ,pp. : 1-11

Adis International

Access to resources Recommend Favorite

Simple method for revealing of false negative results of urine morphine caused by adulterants

By Hedayati M.   Tajic A.   Daneshpour M. S.   Kazemi A.  

Journal of Substance Use, Vol. 13, Iss. 5, 2008-10 ,pp. : 319-324

Radcliffe Press

Access to resources Recommend Favorite